Stichting Kinderoncologie Nederland

What Stichting Kinderoncologie Nederland does

Stichting Kinderoncologie Nederland (SKION), founded in 2002 and headquartered in Utrecht, is an independent Dutch foundation (stichting) with ANBI public benefit status that develops, authorizes, and evaluates national clinical guidelines for pediatric oncology. The organization serves as the institutional quality counterweight to the Prinses Máxima Centrum, where virtually all pediatric oncology treatment and research in the Netherlands is centralized. SKION also operates a professional network platform connecting 14 shared care centers (3 academic, 11 peripheral) across the country, with 31+ professionals in the SKION Raad and 400+ attendees at annual SKION & Shared Care Days.

The foundation's core technical assets include the Metro Map methodology for visually mapping care pathways from diagnosis to follow-up, and proprietary evaluation software developed by the Evaluatiedesk that uses openEHR standards (archetypes and Guideline Definition Language) to extract structured data from electronic patient records and automate guideline adherence benchmarking. Since 2021, SKION has authorized 14 national guidelines covering conditions such as osteosarcoma, fertility preservation, febrile neutropenia, low-grade glioma, and Fanconi anemia, with 11 guidelines currently under evaluation. The portfolio is supported by a process guidance service and a handbook co-developed with the Richtlijn Unit of the Prinses Máxima Centrum.

SKION's revenue model is dominated by a single financing arrangement with the Prinses Máxima Centrum (€458,145 in 2025, representing ~96% of €477,812 total income), supplemented by episodic donations/legacies and event sponsorships. As of January 2026, the organization completed the SKION 3.0 transition, transferring guideline authorization and evaluation tasks to the Prinses Máxima Centrum's quality department, along with €388,711 from the guidelines reserve and two policy staff members. Post-transition, SKION retains its professional networking, educational events (SKION & Shared Care Days), and Cooperative governance role as co-founder alongside VKKN (Vereniging Kinderkanker Nederland).

Name

Stichting Kinderoncologie Nederland

Legal name

Stichting Kinderoncologie Nederland

Website

https://www.skion.nl

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

SKION is an independent Dutch foundation that develops, authorizes, and evaluates national clinical guidelines for pediatric oncology, serving healthcare professionals across 14 shared care centers and the Prinses Máxima Centrum in the Netherlands through proprietary evaluation software and professional network events.

Ownership category

akta.pro rank

Product category

Pediatric Oncology Clinical Guidelines

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

akta.pro secondary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

Keywords

• Pediatric oncology guidelines
• Clinical guideline development
• Evidence-based medicine
• Healthcare quality evaluation
• Shared care networking

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Financing from Prinses Máxima Centrum: SKION receives financing from Prinses Máxima Centrum voor Kinderoncologie B.V. as per the cooperation agreement. In 2024 this was €435,582, in 2025 this was €458,145.
2. Donations and Legacies: SKION receives one-time donations and legacies from supporters. In 2024: €21,357 from one legacy. In 2023: €515,645 from two legacies.
3. Sponsorships for SKION-dagen: Sponsors contribute to the SKION-dagen events. In 2024: €16,529 from sponsors.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

SKION develops, authorizes, and evaluates national clinical guidelines for pediatric oncology in the Netherlands, using its proprietary Metro Map care-pathway methodology and Richtlijnevaluatie Software built on openEHR standards. The foundation also provides process guidance to healthcare professionals developing guidelines and facilitates professional networking through the SKION Raad council, SKION-dagen, and Shared Care Days. Since 2026, guideline authorization and evaluation activities have been transferred to the quality department of the Prinses Máxima Centrum.

Product overview

SKION (Stichting Kinderoncologie Nederland) is an independent foundation focused on improving the quality of pediatric oncology care in the Netherlands through the development, authorization, and evaluation of national clinical guidelines. The core offerings include the Metro Map methodology for visually mapping care pathways, proprietary evaluation software for assessing guideline compliance and outcomes using openEHR standards, and process guidance services to support healthcare professionals in guideline development. SKION maintains a comprehensive portfolio of clinical guidelines covering conditions such as osteosarcoma, fertility preservation, febrile neutropenie, low-grade glioma, Fanconi anemia, and various supportive care topics. The organization also facilitates the SKION & Shared Care Days educational events for professionals in pediatric oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• SKION-richtlijnen (Clinical Guidelines Portfolio)
• Metro Map methodology
• Richtlijnevaluatie Software (Evaluation Software)
• Procesbegeleiding (Process Guidance)
• SKION-dagen & Shared Care Days

Quantifiable outcome

• 86% of children in the Netherlands are alive 5 years after cancer diagnosis (IKNL, 2025)
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Prinses Máxima Centrum voor KinderoncologiecoreStrategic or Co-development Partner · 1 January 2021SKION and Prinses Máxima Centrum maintain a close partnership. SKION is a co-founder of the Máxima and member of the Cooperation. The organizations collaborate on guideline development and evaluation, with SKION providing independent oversight. In 2025, guideline evaluation activities were transferred to the Máxima's Quality department.
• 14 Shared Care CenterscoreStrategic or Co-development PartnerSKION collaborates with 14 shared care centers (3 academic, 11 peripheral) across the Netherlands. These hospitals provide pediatric oncology care closer to home. Examples include Amsterdam UMC, Erasmus MC, UMC Groningen, and various regional hospitals.
• Vereniging Kinderkanker Nederland (VKKN)coreStrategic or Co-development PartnerTogether with VKKN (parents' association), SKION guards the mission of the Máxima. Both are members of the Cooperation and are co-founders of the Prinses Máxima Centrum. VKKN supports families with children with cancer through information, activities, and advocacy.
• Trial & Data Centrum Prinses Máxima CentrumcoreTechnology or IntegrationSKION collaborates with the Trial & Data Centrum on guideline evaluation. Together they developed the evaluation desk and proprietary evaluation software using openEHR standards for data extraction and quality monitoring.
• Richtlijn Unit MáximacoreStrategic or Co-development PartnerIn 2024, SKION started a collaboration with the Richtlijn Unit of the Máxima to promote and guide the development and use of qualitative guidelines in pediatric oncology. Together they developed a handbook for guideline development.
• Nederlands Kanker Collectief (NKC)minorStrategic or Co-development PartnerNKC is a collaboration initiated by IKNL, KWF, and NFK. SKION is part of the collective and contributed to the Dutch Cancer Agenda: 20 goals to reduce the impact of cancer on society.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Prinses Máxima Centrum voor Kinderoncologie: The centralized Dutch pediatric oncology treatment and research center, co-founded by SKION. Now absorbs SKION's guideline authorization and evaluation functions under SKION 3.0; operates the Trial & Data Centrum that collaborates with SKION's evaluation desk.
• Children's Oncology Group (COG): The world's largest pediatric oncology research cooperative, comprising200+ institutions developing and evaluating treatment guidelines for childhood cancers. Comparable as a guideline-developing and clinical-quality organization, though US-based and substantially larger.

Direct peers

• IKNL (Integraal Kankercentrum Nederland): The Netherlands' comprehensive cancer registry and quality institute providing incidence, survival, and treatment data — including the IKNL data SKION cites (551 diagnoses/year, 86% 5-year survival). Comparable as a Dutch cancer quality and evidence organization.
• SIOP Europe (European Society for Paediatric Oncology): European professional society for pediatric oncology clinicians and researchers, coordinating the European Reference Network for Paediatric Oncology (ERN PaedCan) and clinical guideline development across Europe. Most direct international peer to SKION's guideline and network work.
• Vereniging Kinderkanker Nederland (VKKN): Dutch parents' association for children with cancer; co-founder of Máxima alongside SKION and holder of member B in the Cooperative. Comparable as a co-steward of the Dutch pediatric oncology mission and SKION's institutional counterpart within the Cooperative governance structure.
• Stichting Dutch Hospital Data (DHD): Dutch foundation collecting and analyzing hospital administrative and quality data for benchmarking and quality improvement. Comparable as a small Dutch non-profit using health data for clinical quality monitoring and benchmarking — similar operating model to SKION's evaluation desk.

Others

• KWF Kankerbestrijding (Dutch Cancer Society): The Netherlands' primary cancer-focused fundraising foundation; co-initiator of the Nederlands Kanker Collectief alongside SKION. Comparable as a Dutch non-profit stewarding cancer research funding and patient advocacy.
• Nederlandse Federatie van Kankerpatiënten (NFK): Dutch federation of 19 cancer patient organizations; co-initiator of the Nederlands Kanker Collectief and contributor to the Dutch Cancer Agenda. Comparable as a Dutch non-profit cancer stakeholder organization.

Regional players

• European Medicines Agency (EMA) — Pediatric Committee: EU regulator developing pediatric oncology regulatory frameworks and supporting pediatric investigation plans. Adjacent to SKION's guideline work as the European-level public sector institution setting pediatric oncology standards.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stichting-kinderoncologie-nederland

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stichting Kinderoncologie Nederland